SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is currently a focal point for community debate, driven by a recent Google research paper highlighting its quantum-resistant technology and ongoing institutional adoption discussions. While some investors remain highly bullish on its long-term potential and infrastructure utility, others are actively criticizing its price performance and expressing skepticism regarding a significant recovery.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending amid intense community speculation regarding institutional adoption, integration with global banking rails, and the potential passage of the Clarity Act. Investors are actively debating the token's long-term utility against market volatility, with many monitoring institutional ETF inflows and upcoming partnerships for signs of a breakout.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point for investors as the community anticipates the impact of upcoming clinical data readouts and the potential lifting of regulatory holds. Traders are actively debating whether these binary events will trigger a significant short squeeze given the high short interest, or if broader biotech market volatility will maintain pressure on the stock price.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is currently facing significant volatility driven by concerns over its recent convertible notes offering and CEO stock sales, leading to community frustration regarding management execution despite the long-term potential of its Casgevy commercialization and diverse gene-editing pipeline. Investors are actively debating the likelihood of a buyout or strategic partnership, while some utilize the dip to accumulate shares based on belief in the company's strong cash position and upcoming 2026 clinical data readouts.

TokenFi aims to simplify the crypto and asset tokenization process and eventually become the foremost tokenization platform in the world.  The tokenization industry is projected to be a $16 trillion industry by the year 2030. BlackRock, the world’s biggest institutional investor with $10 trillion of assets under management, strongly believes in the industry’s potential, which they call "the next evolution in markets”.  TokenFi is launched by the highly experienced and connected Floki team that launched the popular Floki token that went to an ATH valuation of $3.5 billion. They will be leveraging this same experience to make TokenFi the number one tokenization platform in the industry.

TokenFi

TokenFi is gaining traction as community members highlight its role in the expanding Real World Asset (RWA) and tokenization sector, specifically pointing to recent exchange listings and the ongoing development of its ecosystem. The community remains highly focused on the project's utility, frequent product updates, and its close strategic ties to the Floki ecosystem.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is capturing investor attention as the AI industry faces significant volatility, with participants actively debating the impact of recent security breaches at competitor firms and the company's long-term potential in data training for defense and robotics. Discussions center on technical chart patterns, the stock's role in the AI supply chain, and whether recent consolidation signals a future breakout or further downside.

Kinsale Capital Group, Inc. is a property and casualty insurance company, which engages in the provision of the excess and surplus lines market in the U.S., where it can use its underwriting expertise to write coverages for hard-to-place, small business risks, and personal lines risks. The company was founded by Michael P. Kehoe on June 3, 2009 and is headquartered in Richmond, VA.

Kinsale Capital Group Inc

Kinsale Capital Group is trending as investors weigh strong profitability and growth in the specialty insurance sector against recent earnings estimate misses and analyst downgrades. Community discussions are centered on whether the company's premium valuation is justified by its disciplined underwriting and tech-driven cost advantages, even as some market participants monitor broader industry margin pressures.

Innventure, Inc. operates companies with a focus on transformative, sustainable technology solutions acquired or licensed from multinational corporations. It focuses on sourcing promising technologies from multinational corporations and transforming them into successful standalone businesses. The firm acts as an entrepreneurial platform that acquires and commercializes their innovations to deliver shared value for multinational corporations. The company was founded by Michael Otworth and John S. Scott on October 9, 2023 and is headquartered in Orlando, FL.

Innventure inc.

Innventure is seeing heightened market attention driven by its subsidiary Accelsius, which is gaining visibility for its two-phase liquid cooling technology essential for high-performance AI data centers. Investors are actively discussing the stock's potential as a long-term infrastructure play, often drawing parallels to other sector participants while debating the company's valuation, dilution risks, and speculative upside.

FLOKI is a community-driven, multi-chain utility token that powers a broad ecosystem including decentralized gaming, finance, and educational platforms. Originally evolving from a meme-based asset, the project now focuses on a utility-driven model centered around three pillars: community engagement, technical utility, and global charity work, balancing this ecosystem growth with social impact, such as building schools in developing nations like Ghana and Nigeria.  Key features include Valhalla, an NFT metaverse game where the token serves as the primary currency for capturing creatures and upgrading characters. The ecosystem also features the FlokiFi Locker for securing digital assets and the University of FLOKI for web3 education,with real-world integration facilitated through a prepaid debit card for everyday purchases at global stores. Staking FLOKI allows users to earn rewards in a sister token.  The project is led by a group of core advisors known by pseudonyms such as Sabre and B (The Viking) and is officially backed by DWF Labs, a major digital asset investment firm and market maker. While a small tax on decentralized trades helps fund development, value moves through the system as users utilize the token to pay for in-game items, access asset-locking services, or purchase merchandise.

Floki Token

Floki is capturing community attention as holders weigh the impact of recent ecosystem expansions, including exchange-traded product listings and new trading bot features, against broader market volatility. Discussions are heavily focused on the token's long-term utility, development milestones like Valhalla, and a collective belief in a pending altcoin market rotation.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Vicor Corp. is experiencing intense market attention following strong quarterly results that surpassed analyst expectations, driven by rising demand for its power conversion modules in AI data centers. While some market participants are wary of overvaluation and persistent insider selling, the community is actively debating the stock's potential as a long-term infrastructure play, often citing its strategic role in vertical power delivery for next-generation GPU architectures.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Is Brookdale Senior Living (BKD) Outperforming Other Medical Stocks This Year?

Here is how Brookdale Senior Living (BKD) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.

Coherus Oncology (NASDAQ:CHRS) Stock Price Passes Above Two Hundred Day Moving Average   - Time to Sell?

Coherus Oncology (NASDAQ:CHRS) Shares Cross Above Two Hundred Day Moving Average - Should You Sell...

Coherus Oncology, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Hold" by Brokerages

Coherus Oncology, Inc. (NASDAQ:CHRS - Get Free Report) has earned an average recommendation of "Hold" from the five research firms that are presently covering the firm, Marketbeat reports. One...

Coherus Oncology (NASDAQ:CHRS) Stock Price Passes Above 200 Day Moving Average   - Should You Sell?

Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above 200 Day Moving Average - Time to Sell...

Coherus Oncology (CHRS) Upgraded to Buy: Here's What You Should Know

Coherus Oncology (CHRS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Coherus Oncology (NASDAQ:CHRS) Shares Pass Above Two Hundred Day Moving Average   - Here's What Happened

Coherus Oncology (NASDAQ:CHRS) Share Price Crosses Above Two Hundred Day Moving Average - What's Next...

Is Biodesix (BDSX) Stock Outpacing Its Medical Peers This Year?

Here is how Biodesix, Inc. (BDSX) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.

Coherus Oncology Pivots to Immuno-Oncology, Touts LOQTORZI Growth and New Pipeline at Citizens Conf.

Coherus Oncology (NASDAQ:CHRS) used its presentation at the Citizens Life Sciences Conference to outline its transition into what CEO Denny Lanfear described as an innovative oncology company focused...

Coherus Oncology (NASDAQ:CHRS) Upgraded at Wall Street Zen

Wall Street Zen raised Coherus Oncology from a "sell" rating to a "hold" rating in a research note on Saturday...

Coherus Oncology Q4 Earnings Call Highlights

Coherus Oncology (NASDAQ:CHRS) outlined progress on its transition to an innovative oncology company during its fourth-quarter and full-year 2025 earnings call, highlighting a growing commercial base...

Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of biosimilar therapeutics. Its products include UDENYCA and LOQTORZI. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.

Current Price	$1.75
Prev Close	$1.76
Open	$1.76
Dividend Yield	0.00%
50-Day Moving Average	$1.72
Beta	1.84
Avg. Volume	1.48M
PE Ratio	-1.20

52-Week High	$2.62
52-Week Low	$0.71
Market Capitalization	$271.42M
EPS (Annual)	-$1.45
Price to Book	3.48
Revenue Per Employee	$286,884.35

CHRS
Coherus Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CHRS News

CHRSCoherus Biosciences Inc